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Abstract
Background: Temporomandibular joint (TMJ) inflammation in patients with juvenile idiopathic arthritis (JIA) can lead
to orofacial pain and malfunction of the TMJ. Intra-articular corticosteroid injections (IACI) have been suggested as a
treatment modality against TMJ arthritis-related orofacial signs and symptoms. However, knowledge of the effect-
durability of these injections remains unanswered. The aim of this pilot study was to evaluate the short and long-term
effects of IACI on orofacial symptoms in a prospective observational study based on pre-specified clinical examination
standards.
Methods: Thirteen patients with JIA and arthritis-related orofacial signs and symptoms were included in this prospective
pilot study (median 17.2 years, IQR 15–18.4 years). All patients received TMJ IACI (11 bilateral and two unilateral) due to an
insufficient response to previous pain-management treatments. Three standardized clinical examinations were carried out:
T1 prior to treatment, T2 short-term follow-up (mean 34 days post-treatment), T3 long-term follow-up (mean 333 days
post-treatment).
Results: Significant pain reduction was observed at the short-term follow-up (T2). Resolution of orofacial pain after IACI
was a rare finding at T2. Generally, the pain significantly worsened between T2 and T3 examinations. The reported pain
levels rose between T2 and T3 indicating a loss of effect of the IACI at the long-term follow-up examination (T3). Non-
significant improvements in TMJ mobility were observed at T2 and T3.
Conclusion: Our results suggest a palliative (not curative) effect of IACI for TMJ arthritis-related orofacial symptoms in
patients with long-term orofacial pain complaints. The short-term improvements in signs and symptoms were partly
resolved at the long-term follow-up.
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Background
In patients with juvenile idiopathic arthritis (JIA), tem-
poromandibular joint (TMJ) involvement may interfere
with craniomandibular joint and muscle function [1, 2].
TMJ pain and functional impairment may not necessar-
ily be present in patients with TMJ arthritis [3, 4]. How-
ever, when present, the main complaints associated with
TMJ arthritis are reduced maximal opening capacity,
orofacial pain during TMJ function, fatigue of the jaws,
and TMJ crepitation [1, 2, 5]. In some patients the TMJ
arthritis-related orofacial pain develops into a more
chronic stage which may have a significant impact on
the quality of life of the individual patient [6]. It is still
unknown whether orofacial pain origins from the actual
inflammation or from a TMJ dysfunction preceding mor-
phological erosive changes of the joint components.
The current limited level of evidence suggests poten-
tial beneficial properties of intra-articular corticosteroid
injections (IACI) in patients with JIA and TMJ arthritis-
related orofacial symptoms. However, knowledge of the
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durability of the effect of these injections needs to be
elucidated. In addition, knowledge of the long-term im-
pact of IACI on mandibular growth is unavailable when
this treatment modality is administered in growing pa-
tients [7].
The aim of the present study was to conduct a pilot
study to evaluate the short-term and long-term effects of
a single IACI against TMJ arthritis-related orofacial
signs and symptoms in a prospective, observational,
intention-to-treat-analysis based on pre-specified clinical
examination standards.
Methods
Thirteen patients diagnosed with JIA according to the
ILAR criteria [8] were included in the study (all females,
median 17.2 years, IQR 15–18.4 years). The included pa-
tients represent all JIA patients consecutively referred
for treatment with IACI in the TMJ between February
2011 and July 2012 at the Section of Orthodontics, Aar-
hus University. The patients had a diagnosis of TMJ
arthritis based on clinical and radiological findings
(cone-beam): At the time of referral all included individ-
uals had findings indicating previous/present TMJ arth-
ritis such as dentofacial growth disturbances and
obvious abnormal radiological TMJ findings (degener-
ation/flattening) in addition to the presence of clinical
symptoms. The JIA subtypes are described in Table 1.
The indication of referral to IACI treatment was a long-
standing history of refractory TMJ arthritis-related oro-
facial symptoms with an insufficient response to previ-
ous pain-management treatments (oral splints,
physiotherapy, NSAIDs, MTX and/or biologics). The de-
cision of IACI therapy was based on the following pa-
rameters; I) A patient history of severe refractory TMJ
arthritis-related orofacial pain, II) functional and/or os-
seous indications of TMJ arthritis, III) insufficient re-
sponse to previous treatment. The candidates had all
received a cone-beam computerized tomography before
the treatment with IACI for the assessment of osseous
degenerations; no contrast-enhanced MRIs had been
conducted. All patients received non-imaging guided
IACI with triamcinolone hexacetonide (20 mg/injection)
based on a standardized injection protocol by an experi-
enced and trained operator (TKP). Eleven patients re-
ceived bilateral TMJ injections and two had unilateral
injections. Throughout the study, each patient received
three standardized clinical examinations; prior to treat-
ment (T1), at the clinical short-term follow-up examin-
ation defined as T2 (34 days post-treatment, range: 7–
58 days), and an additional long-term post-treatment
examination defined as T3 (mean 333 days post-
treatment, range 190–600 days). The standardized exam-
ination consisted of a pain-questionnaire completed by
the patient and a clinical examination completed by the
treating orthodontist. The treatment modality of TMJ
IACI in patients with JIA complies with the rules of the
Danish Health and Medicines Agency for clinical
pediatric rheumatology. The Danish Data Protection
Agency approved handling of the confidential data
(No.1-16-02-272-14), and all included patients approved
the use of the patient files and gave consent to publish
the material in accordance with the rules of the Danish
Health and Medicines Agency. Outcome assessment was
based on the following pain variables:
Pain-frequency
Patients were asked to report the frequency of their oro-
facial symptoms on a 5-point Likert scale: 0) Never pain;
Table 1 Clinical characteristics of 13 patients with JIA with
long-term symptomatic TMJ arthritis
Cohort characteristics n = 13
Females, number (percentage) 13 (100 %)
















Combination of 2 to 3 drugs 4











aThis is the mean age and standard deviation of the 12 patients excluded the
outlying patient with the age of 34 years.b Time since JIA diagnosis. cTime
since TMJ arthritis diagnosis. TMJ temporomandibular joint
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1) pain less than once a week; 2) pain 1–3 times a week;
3) pain 4–6 times a week; 4) pain several times a day;
and 5) pain all the time.
Pain intensity
The patients were asked to assess the average orofacial
pain intensity on a non-verbal visual analogue scale
(VAS) of 100 mm, where the left extreme represents “no
pain” and the right extreme represents the “worst im-
aginable pain”.
Pain-index
A composite variable combining the aspects of orofacial
pain frequency and intensity; calculated as the pain fre-
quency multiplied by the pain intensity, with a score
range between 0 and 500. This variable was used to cal-
culate the relative change in pain between the pre-
treatment levels and the short and long-term follow-up
pain levels.
Secondary outcome variables describing changes in
TMJ mobility were measured in accordance with a pre-
viously described standardized examination protocol [9].
Maximal incisal opening
The maximal unassisted incisal opening capacity was
measured inter-incisally with a metallic ruler positioned
on the incisal edge of the lower incisors. The inter-
incisal vertical overlap was accounted for in the
measurement.
Laterotrusion
The maximal unassisted lateral movement of the lower
jaw from the most left position to the most right pos-
ition measured in mm.
Protrusion
The maximal unassisted forward movement of the lower
jaw measured in mm.
Statistics
After the data were tested for normal distribution general
differences in pain variables and functional variables be-
tween T1, T2 and T3 were assessed by ANOVA tests with
paired Student’s t-tests serving as post-ANOVA tests.
Post-Anova tests were only performed in outcome vari-
ables where a statistical significant difference was ob-
served in the primary ANOVA test. Changes in the
categorical data concerning pain frequency were statisti-
cally analyzed using a Kruskal Wallis Rank-sum test with
Wilcoxon matched-paired rank tests serving as post-tests.
A p value of less than 0.05 was considered significant.
Results
Radiological signs of osseous TMJ degenerations were
observed in all TMJs receiving IACI. Patient characteris-
tics are depicted in Table 1. Two patients had their treat-
ment changed during the observation: One patient had a
change in the medication between T1 and T2; systemic
anti-TNF-α (Enbrel) treatment was added to the treat-
ment of methotrexate after experiencing no effect of the
bilateral TMJ IACIs. Another patient received additional
bilateral TMJ IACIs between T2 and T3 due to a lack of
effect of the initial IACI treatment. Both of these pa-
tients were included in the final analysis based on a last-
observation-carried-forward strategy. No adverse reac-
tions were observed directly in relation to the IACI
procedure.
Pre- and post-treatment pain and functional values are
depicted in Table 2 and Fig. 1. The Kruskal Wallis and
the ANOVA tests revealed statistical intra-group differ-
ences between the three time-points in relation to all
three pain outcome variables. Further intra-group differ-
ences were revealed during post-testing and these are re-
ported below. No general primary significant differences
were observed for any of the functional outcome
variables.
Pain-variables
High pre-treatment pain levels were seen at T1 with a
mean pain intensity of 62.7 (VAS scale 0–100 mm) and
a reported average pain frequency of “several times a
day”. At the short-term follow-up (T2) pain-frequency,
pain-intensity and pain-index were all significantly re-
duced when compared to the pre-treatment T1 levels.
However, at the long-term T3 follow-up only the pain-
frequency remained significantly reduced compared to
the pre-treatment T1 level. The pain-intensity and also
the pain-index variables significantly worsened between
T2 and T3 as illustrated in Table 2; especially patients
with high pre-treatment pain levels had a tendency to
worsen between T2 and T3.
Relative pain-index reduction
Pain cessation was rare at the follow-ups and was only
experienced in three patients at the short-term follow-
up (T2) and in one patient at the long-term T3 follow-
up (Fig. 1d). At T2, eleven patients reported a relative
pain-index reduction when compared to pre-treatment
levels; nine patients (69 %) had experienced a reduction
of more than 50 per cent at T2 (Fig. 1d). Between the
short- and the long-term examination 7 patients experi-
enced an aggravation of the reported pain-index levels
potentially indicating a reduction in the effect of the
IACI treatment (Fig. 1d). However, six patients reported
a relative T3 pain-index reduction of more than 50 per
cent compared to the pre-treatment T1 levels.
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TMJ mobility
The ANOVA test documented no significant intra-group
changes in any of the outcome variables reflecting TMJ
mobility (Table 2). Despite this finding, Fig. 2 reveal
great inter-patient variation in the functional changes
after IACI and at the short-term examination clinical
relevant improvements are seen in some patient.
Discussion
We observed a significant pain-level reduction in the
majority of patients at the short-term follow-up evalu-
ation pointing towards a beneficial short-term effect of
IACI. Although statistical significant symptomatic im-
provements of TMJ arthritis were observed, this pilot
study shows a considerable inter-patient variation in the
response to IACI treatment and total resolution of orofa-
cial pain was a rare finding. Between the short-term (T2)
and the long-term (T3) follow-up, exacerbation of pain-
levels was seen in seven out of thirteen patients suggesting
a loss of effect of the IACI at the long-term follow-up
examination for some of the patients. Aggravation of pain
between the short-term and the long-term follow-up was
most pronounced in patients with high T1 pre-treatment
pain levels. This finding is somewhat in conflict with pre-
vious reports on IACI for the treatment of TMJ arthritis-
related signs and symptoms where a better response has
been reported from IACI TMJ treatment [10–12]. This
difference in the response to the treatment in our study
could be explained by the included group of patients
where a majority of the adolescent and adult JIA patients
had a long-term history of pain complaints and an insuffi-
cient response to previous orofacial pain management
strategies. Previous studies have included JIA patients of
younger age and with shorter duration of TMJ arthritis
[10–12]. However, when assessing our results it still worth
to notice that six out of the thirteen patients had a relative
pain-index reduction of more than 50 per cent at the
long-term follow-up compared to the pre-treatment levels;
especially, reduction pain frequency was observed be-
tween T1 and T3. This is a positive finding related to this
group of patients with persistent and long-term pain is-
sues failing other pain treatment strategies. However, the
study design does not allow us to assess if this is due to
fluctuation of orofacial symptoms or the real effect of the
treatment with IACI since no control group is included.
The present group of patients gives the impression
of a pain problem not only related to TMJ arthritis
but also to the morphological changes within the
TMJ caused by the arthritis. The results presented in
this study, therefore, are probably not generalizable
to a whole JIA population since the present group of
patients is a unique group of patients suffering from
refractory TMJ arthritis-related pain. However, from
a clinical point of view our results contribute with
new knowledge since it illustrates that achievement
of an acceptable treatment result in this group of
patients is indeed a very challenging task. Secondly,
this is the first longitudinal study to address the
treatment effect with IACI in this specific patient
group with refractory orofacial symptoms. It is pos-
sible that a population-based group of JIA patients
with TMJ involvements could have a better outcome
of IACI in relation to arthritis-induced orofacial
pain.
Despite the fact that no significant improvements in
TMJ mobility changes were observed throughout the
study, minor short-term and long-term improvements
were seen after the treatment with IACI. The clinical rele-
vance of the long-term TMJ mobility improvements de-
scribed is debatable since only short-term improvement in
TMJ mobility exceeds the variation within the measure-
ment technique used to assess the outcome variables exam-
ined [9]. Our TMJ mobility findings are therefore in line
with previous reports on the effect of IACI on mouth

















Pain frequency (1–5) 4.5¤ 2.3¤ 2.7¤ 2.2 1.8 0.4 0.0001d T1 > T2 = T3e
Pain intensity (VAS 100 mm) 65.2 (19.9) 27.5 (22.2) 49.3 (24.8) −37.8 (31.4) −16.1 (27.7) 21.7 (22.7) 0.0006 T1 > T2 < T3,
T1 = T3,
Pain index (Frequency x intensity) 295.5 (114.2) 84.9 (91.7) 154.7 (134.9) −210.7 (149.1) −140.8 (136.4) 69.8 (114.4) 0.0002 T1 > T2 < T3,
T1 > T3,
Function
Mouth opening (mm) 35.5 (7.1) 40.3 (5.8) 39.3 (6.5) 4.9 (5) 3.9 (7.5) −1 (6.5) 0.24 c
Laterotrusion (mm) 12.3 (4.8) 14.9 (2.9) 15.8 (5.4) 2.6 (3.4) 3.5 (3.5) 0.9 (4.2) 0.13 c
Protrusion (mm) 5.4 (1.5) 6.3 (1.7) 7.2 (2.9) 0.9 (2.1) 1.8 (2.7) 0.9 (2.9) 0.09 c
aANOVA is used if nothing else i stated. bStudents paired T-test is used if nothing else is stated. A significant difference (p < 0.05) is indicated with”<” or “>”. cPost-Anova
tests were only performed in outcome variables were a statistical significant difference was observed in the primary ANOVA test. dKruskal Wallis Ranksum test.
eWilcoxon matched paired Rank test. ¤ A mean value has been calculated despite of the categorical nature of this variable
Stoustrup et al. Pediatric Rheumatology  (2015) 13:62 Page 4 of 6
opening capacity where only minor improvements, with
limited clinical value, have been obtained [10, 13, 14].
The current limited evidence available suggests potential
beneficial properties of IACI against TMJ arthritis-related
symptoms. At this point no clear scientific evidence
substantiates the effect of IACI in terms of improvement in
orofacial function [7]. From a clinical point of view, our
findings support the present clinical indications for the use
of IACI against TMJ arthritis. However, caution should be
applied before the use of IACI in younger patients since
Fig. 1 Pain related outcomes. Changes in outcome variables related to pain before and after corticosteroid injection of the TMJ in 13 patients
with JIA. Dotted lines indicate the mean values at each point of time. a changes in pain frequency, b changes in pain intensity, c changes in
painindex (frequency x intensity), d Relative pain-scores at different timepoints
Fig. 2 Outcomes in TMJ mobility. Changes in outcome variables related to TMJ mobility before and after corticosteroid injection of the TMJ in 13
patients with JIA. Dotted lines indicate the mean values at each point of time. a changes in maximal mouth opening, b changes in total
laterotrusion, c changes in protrusion
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concerns about the impact of IACI on mandibular growth
remain an unanswered and relevant consideration [7]. An-
other concern in relation to TMJ IACI is the risk of devel-
oping intra-articular calcifications which may reduce the
TMJ function: A recent publication by Lochbühler et al.,
observed intra-articular calcifications in 21 percent of the
TMJs that received treatment with IACI [15].
Important strengths of this study were the prospective,
standardized, intention-to-treat design. This is the first
study to use this design within this specific field and treat-
ment modality. Notable limitations were the low number of
included patients, the lack of a control group to account for
the bias of the placebo-effect, and the selection bias during
the referral procedures. Another limitation was the fact that
no pre-treatment MRI was performed in any of the pa-
tients. However, recent research suggests only a limited as-
sociation between clinical findings and TMJ MRI findings
in patients with JIA [16]. In addition, a recent report calls
for a general debate about the MRI-indications for the use
of IACI therapy, since MRI contrast-enhancement seems to
be a normal finding in the soft tissue and the mandibular
condyle of the TMJ in non-arthritic children and adoles-
cents [17].
Conclusion
In conclusion, our results suggest a palliative (not curative)
effect of IACI for TMJ arthritis-related orofacial symptoms
in patients with long-term orofacial pain complaints not
responding to other pain management strategies. The
short-term improvements in signs and symptoms after
IACI were partly resolved at the long-term follow-up. Fu-
ture studies in accordance with evidence based standards,
involving more patients, are needed in order to make more
solid conclusions. Based on the findings of this pilot-study
with TMJ IACI, future, prospective, long-term follow-up
studies are planned.
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